Introduction
Recent clinical discourse regarding endovascular thrombectomy (EVT) for large core acute ischemic stroke (AIS) has highlighted significant variability in trial eligibility criteria. While EVT is the established standard for small-core strokes, its efficacy in patients with extensive baseline damage—"large core" strokes—remains a critical frontier in neurointerventional surgery. The ANGEL-ASPECT trial (NCT 04551664), currently the only large core trial focused on the Chinese population, offers a unique methodological perspective that addresses several ethical and diagnostic challenges identified in contemporary debates.
The Challenge of Patient Selection
The primary hurdle in large core trials is the accurate definition and measurement of the ischemic core. Two dominant methods currently exist:
- Alberta Stroke Program Early CT Score (ASPECTS): A visual 10-point scoring system for non-contrast CT. While rapid, it suffers from high inter-rater variability.
- CT Perfusion (CTP) or Diffusion-Weighted MRI (DWI-MRI): Automated software that calculates tissue volume. While objective, these can overestimate damage in the hyperacute phase, potentially excluding patients who might still benefit from reperfusion.
The central tension in trial design is ensuring that patients who are already known to benefit from EVT are not randomized into "no-treatment" control groups, while simultaneously identifying those with cores so large that treatment would be futile or harmful.
The ANGEL-ASPECT Methodology
The ANGEL-ASPECT trial employs a tiered, hybrid imaging strategy designed to minimize subjectivity and maximize the identification of "true" large cores. Unlike the SELECT-2 trial, which relies heavily on CTP/DWI-MRI, ANGEL-ASPECT uses a multi-step approach:
- Tier 1 (Primary Inclusion): Patients presenting within 24 hours with an ASPECTS score of 3–5 are enrolled based on visual CT assessment alone.
- Tier 2 (Secondary Validation): Advanced imaging (CTP or MRI) is used as a "tie-breaker" in specific scenarios, such as when the ASPECTS score is >5 but the patient is in the late window (>6 hours), or if the score is <3.
- Volume Thresholds: The trial defines a large core as a volume between 70–100 cc.
Comparative Insights and Ethical Considerations
A key differentiator of ANGEL-ASPECT is its handling of the "gray zone"—patients with core volumes between 50–70 cc. Existing evidence suggests this group likely benefits from EVT. By excluding them from the trial, the researchers avoid the ethical dilemma of randomizing patients to a potentially inferior "no-treatment" arm.
Furthermore, the trial expands the treatment window to 24 hours, testing the durability of EVT's benefit in large cores well beyond the traditional 6-hour limit. In comparison to other global trials such as TENSION, LASTE, and SELECT-2, ANGEL-ASPECT is unique in its specific volume range and its focus on the Asian population, where intracranial atherosclerotic disease is more prevalent.
Preliminary Observations and Future Directions
Current enrollment data indicates that CTP-based inclusion accounts for only approximately 10% of the total study population. This suggests that traditional CT remains a robust tool for identifying the majority of large core cases, with advanced imaging serving as a vital safety valve for ambiguous presentations.
The ultimate goal of the ANGEL-ASPECT trial is to determine if EVT provides a functional benefit regardless of the presence of a "penumbra" (salvageable tissue) on advanced imaging. If successful, this could streamline stroke workflows by allowing clinicians to bypass time-consuming perfusion scans and move directly to intervention, adhering to the principle that "time is brain."
Conclusion
The ANGEL-ASPECT trial provides a refined framework for large core stroke research. By balancing subjective visual scores with objective volumetric data and respecting established benefit thresholds, the study design aims to provide definitive evidence for EVT in a challenging patient population while maintaining the highest ethical standards in clinical trial methodology.
Summary updated